Scarica l'app Stockscreener
58.88
0.79%
-0.47
Dopo l'orario di chiusura:
58.88
Precedente Chiudi:
$59.35
Aprire:
$59.7
Volume 24 ore:
937.43K
Relative Volume:
0.70
Capitalizzazione di mercato:
$5.62B
Reddito:
$7.50M
Utile/perdita netta:
$-345.91M
Rapporto P/E:
-13.50
EPS:
-4.3602
Flusso di cassa netto:
$-280.51M
1 W Prestazione:
+2.33%
1M Prestazione:
+6.61%
6M Prestazione:
+40.53%
1 anno Prestazione:
+78.26%
Intervallo 1D:
$58.35
$59.70
Intervallo di 1 settimana:
$57.44
$59.99
Portata 52W:
$28.19
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
58.88 | 5.66B | 7.50M | -345.91M | -280.51M | -4.3602 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon to Present at Upcoming Investor Conferences - Yahoo Finance
Xenon Expands 2025 Inducement Equity Incentive Plan - The Globe and Mail
Xenon Pharmaceuticals Amends 2025 Inducement Equity Incentive Plan for Nasdaq Compliance and Employee Attraction 10 - Minichart
Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve - Stock Titan
Certain Restricted Stock Units of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Stock Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Published on: 2026-04-09 12:46:57 - baoquankhu1.vn
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN By Investing.com - Investing.com Australia
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN - Investing.com
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting - Bitget
Xenon brings 48-month epilepsy drug data and Phase 3 results to AAN - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - AOL.com
XENE SEC FilingsXenon Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Aberdeen Group plc Increases Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) climbs 31.7% as epilepsy treatment moves forward - MSN
XENE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
XENE PE Ratio & Valuation, Is XENE Overvalued - Intellectia AI
Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal
XENE Should I Buy - Intellectia AI
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals stock soars 20% in 3 months: Here's why - MSN
How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors - Sahm
Assenagon Asset Management S.A. Invests $5.34 Million in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 Results And US$750 Million Capital Raise - Sahm
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - The Motley Fool
Xenon Pharmaceuticals (XENE) price target increased by 41.64% to 80.01 - MSN
Wolfe Research initiates coverage of Xenon Pharmaceuticals (XENE) with outperform recommendation - MSN
Crude oil rises around 4%; Xenon Pharmaceuticals shares surge - MSN
(XENE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Published on: 2026-03-22 04:08:37 - baoquankhu1.vn
Xenon Pharmaceuticals rallies after pivotal data shows major drop in monthly seizures - MSN
Xenon Pharmaceuticals stock faces pipeline scrutiny amid biotech sector volatility - AD HOC NEWS
JPMorgan Chase & Co. Purchases 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - marketbeat.com
Xenon Pharmaceuticals Shares Jump 20% Over Three Months: The Reasons Explained - Bitget
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why - The Globe and Mail
Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):